Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005956 · ClinicalTrials.gov registry record · NA
Biological Therapy in Treating Patients With Advanced Cancer
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT00005956 is a NA study that has completed, run by Duke University. The registered enrollment target is 3 participants.
The verdict
NCT00005956, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: A person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have advanced cancer that shows no signs of disease following treatment.
Interventions
- BIOLOGICAL therapeutic autologous dendritic cells
- BIOLOGICAL HER-2/neu intracellular domain protein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2000-02 |
| Est. Completion | 2002-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005956
The ClinicalTrials.gov registry entry for NCT00005956 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which therapeutic autologous dendritic cells is the first listed.
NCT00005956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005956 about?
NCT00005956 is a clinical study titled "Biological Therapy in Treating Patients With Advanced Cancer". RATIONALE: A person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have advanced cancer that shows no signs of disease following treatment.
What is the current status of trial NCT00005956?
This trial is currently completed. It is a NA study. The enrollment target is 3 participants. The study started on 2000-02. Estimated completion is 2002-07.
What interventions are being tested in trial NCT00005956?
The interventions under investigation include: therapeutic autologous dendritic cells (BIOLOGICAL), HER-2/neu intracellular domain protein (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005956?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.